Arcus Biosciences Proclaims New Employment Inducement Grants By Investing.com
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, international biopharmaceutical firm targeted…
Ventyx Biosciences’ chief scientific officer sells $29,682 in inventory By Investing.com
John Nuss, the Chief Scientific Officer of Ventyx Biosciences, Inc. (NASDAQ:VTYX), not…
Aura Biosciences CEO Elisabet de los Pinos sells $98,787 in inventory By Investing.com
BOSTON—Elisabet de los Pinos, President and CEO of Aura Biosciences, Inc. (NASDAQ:AURA),…
IDEAYA Biosciences Proclaims IND-Clearance for Werner Helicase Improvement Candidate IDE275 (GSK959) for a Part 1 Examine in MSI-Excessive Stable Tumors By Investing.com
IDE275 (GSK959) growth is progressing into First-in-Human Part 1 scientific trial(s) for…
Precision BioSciences to Take part in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences By Investing.com
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a medical stage gene enhancing…
Avidity Biosciences CEO sells over $1.4 million in firm inventory By Investing.com
In a latest transaction, Sarah Boyce, the President and CEO of Avidity…
IGM Biosciences CEO sells shares value over $45,000 By Investing.com
IGM Biosciences, Inc. (NASDAQ:) CEO and President Fred Schwarzer has offered a…
BofA flags investor doubts as Arcus Biosciences inventory struggles By Investing.com
On Friday, BofA Securities revised its worth goal for Arcus Biosciences (NYSE:),…
Senhwa Biosciences receives US FDA Examine Might Proceed letter for the Part I/II examine of Silmitasertib (CX-4945) together with chemotherapy in kids and younger adults with relapsed refractory s By Investing.com
TAIPEI and SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc.…
Tyra Biosciences hits 52-week excessive, reaching $21.67 By Investing.com
Tyra Biosciences, a number one biotechnology firm, has reached a brand new…
